These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 23042003

  • 1. Low-dose valgancyclovir as cytomegalovirus reactivation prophylaxis in allogeneic haematopoietic stem cell transplantation.
    Serio B, Rosamilio R, Giudice V, Pepe S, Zeppa P, Esposiito S, Pezzullo L, Rocco M, Montuori N, Selleri C.
    Infez Med; 2012; 20 Suppl 2():26-34. PubMed ID: 23042003
    [Abstract] [Full Text] [Related]

  • 2. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation.
    Busca A, de Fabritiis P, Ghisetti V, Allice T, Mirabile M, Gentile G, Locatelli F, Falda M.
    Transpl Infect Dis; 2007 Jun; 9(2):102-7. PubMed ID: 17461994
    [Abstract] [Full Text] [Related]

  • 3. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, Hertzberg M, Gottlieb D, Bradstock K.
    Transpl Infect Dis; 2010 Aug 01; 12(4):322-9. PubMed ID: 20487414
    [Abstract] [Full Text] [Related]

  • 4. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.
    Ruiz-Camps I, Len O, de la Cámara R, Gurguí M, Martino R, Jarque I, Barrenetxea C, Díaz de Heredia C, Batlle M, Rovira M, de la Torre J, Torres A, Aguilar M, Espigado I, Martín-Dávila P, Bou G, Borrell N, Aguado JM, Pahissa A, Spanish Network for Research on Infection in Transplantation (RESITRA/REIPI). Spain.
    Antivir Ther; 2011 Aug 01; 16(7):951-7. PubMed ID: 22024510
    [Abstract] [Full Text] [Related]

  • 5. Low-dose valganciclovir prohylaxis is efficacious and safe in cytomegalovirus seropositive heart transplant recipients with anti-thymocyte globulin.
    Eriksson M, Jokinen JJ, Söderlund S, Hämmäinen P, Lommi J, Lemström K.
    Transpl Infect Dis; 2018 Jun 01; 20(3):e12868. PubMed ID: 29512249
    [Abstract] [Full Text] [Related]

  • 6. Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200 days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study.
    Fleming JN, Taber DJ, Weimert NA, Nadig S, McGillicuddy JW, Bratton CF, Baliga PK, Chavin KD.
    Transpl Infect Dis; 2017 Dec 01; 19(6):. PubMed ID: 28921781
    [Abstract] [Full Text] [Related]

  • 7. Oral Valganciclovir as Preemptive Therapy for Cytomegalovirus Reactivation in Pediatric Hematopoietic Stem Cell Transplant Patients.
    Atay D, Erbey F, Akcay A, Dag A, Ozturk G.
    J Pediatr Hematol Oncol; 2015 Oct 01; 37(7):543-7. PubMed ID: 26207778
    [Abstract] [Full Text] [Related]

  • 8. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
    Stevens DR, Sawinski D, Blumberg E, Galanakis N, Bloom RD, Trofe-Clark J.
    Transpl Infect Dis; 2015 Apr 01; 17(2):163-73. PubMed ID: 25661673
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.
    Park JM, Lake KD, Arenas JD, Fontana RJ.
    Liver Transpl; 2006 Jan 01; 12(1):112-6. PubMed ID: 16382458
    [Abstract] [Full Text] [Related]

  • 10. Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.
    Kim JM, Kwon CH, Joh JW, Ha YE, Sinn DH, Choi GS, Peck KR, Lee SK.
    PLoS One; 2015 Jan 01; 10(5):e0123554. PubMed ID: 25942443
    [Abstract] [Full Text] [Related]

  • 11. Low-dose valganciclovir for cytomegalovirus prophylaxis in intermediate-risk liver transplantation recipients.
    Khan S, Sullivan T, Ali M, Dunn D, Patel G, Huprikar S.
    Liver Transpl; 2018 May 01; 24(5):616-622. PubMed ID: 29500912
    [Abstract] [Full Text] [Related]

  • 12. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K, Nishida T, Asano-Mori Y, Oshima K, Ohashi K, Mori T, Kanamori H, Miyamura K, Kato C, Kobayashi N, Uchida N, Nakamae H, Ichinohe T, Morishima Y, Suzuki R, Yamaguchi T, Fukuda T.
    Biol Blood Marrow Transplant; 2015 Nov 01; 21(11):2008-16. PubMed ID: 26211985
    [Abstract] [Full Text] [Related]

  • 13. Prevention of Cytomegalovirus Reactivation in Haploidentical Stem Cell Transplantation.
    Hammerstrom AE, Lombardi LR, Pingali SR, Rondon G, Chen J, Milton DR, Chemaly RF, Champlin RE, Gulbis A, Ciurea SO.
    Biol Blood Marrow Transplant; 2018 Feb 01; 24(2):353-358. PubMed ID: 28986189
    [Abstract] [Full Text] [Related]

  • 14. Extended Low-Dose Valganciclovir Is Effective Prophylaxis Against Cytomegalovirus in High-Risk Kidney Transplant Recipients With Near-Complete Eradication of Late-Onset Disease.
    Fayek SA, Beshears E, Lieber R, Alvey N, Sauer A, Poirier J, Hollinger EF, Olaitan OK, Jensik S, Geyston J, Brokhof MM, Hodowanec AC, Hertl M, Simon DM.
    Transplant Proc; 2016 Feb 01; 48(6):2056-2064.e1. PubMed ID: 27569944
    [Abstract] [Full Text] [Related]

  • 15. High efficacy and low toxicity of short-course oral valganciclovir as pre-emptive therapy for hematopoietic stem cell transplant cytomegalovirus infection.
    Saleh AJ, Al Mohareb F, Al Rabiah F, Chaudhri N, Al Sharif F, Al Zahrani H, Mohamed SY, Patel M, Rasheed W, Nurgat Z, Bakr M, Ahmed S, Zaidi S, Nasser A, Ibrahim K, Al Abdely H, Aljurf M.
    Hematol Oncol Stem Cell Ther; 2010 Feb 01; 3(3):116-20. PubMed ID: 20890068
    [Abstract] [Full Text] [Related]

  • 16. Half-dose ganciclovir preemptive treatment of cytomegalovirus infection after pediatric allogeneic hematopoietic stem cell transplantation.
    Ju HY, Kang HJ, Hong CR, Lee JW, Kim H, Park KD, Shin HY, Park JD, Choi EH, Lee HJ, Ahn HS.
    Transpl Infect Dis; 2016 Jun 01; 18(3):396-404. PubMed ID: 27041364
    [Abstract] [Full Text] [Related]

  • 17. Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus.
    Liu YC, Lu PL, Hsiao HH, Chang CS, Liu TC, Yang WC, Lin SF.
    Ann Hematol; 2012 Apr 01; 91(4):587-95. PubMed ID: 21997849
    [Abstract] [Full Text] [Related]

  • 18. Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients.
    Heldenbrand S, Li C, Cross RP, DePiero KA, Dick TB, Ferguson K, Kim M, Newkirk E, Park JM, Sudaria-Kerr J, Tichy EM, Ueda KR, Weng R, Wisniewski J, Gabardi S.
    Transpl Infect Dis; 2016 Dec 01; 18(6):904-912. PubMed ID: 27639246
    [Abstract] [Full Text] [Related]

  • 19. Cytomegalovirus reactivation and disease amongst patients with allogeneic haematopoietic stem cell transplantation in Eastern India: Epidemiology, outcome and healthcare cost.
    Kumar M, Roychowdhury M, Kumar J, Harishankar A, Sinha S, Bhave SJ, Chakrapani A, Radhakrishnan V, Nair R, Bhattacharya S, Chandy M.
    Indian J Med Microbiol; 2018 Dec 01; 36(1):49-53. PubMed ID: 29735826
    [Abstract] [Full Text] [Related]

  • 20. Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature.
    Chawla JS, Ghobadi A, Mosley J, Verkruyse L, Trinkaus K, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Uy GL, Westervelt P, DiPersio JF, Vij R.
    Transpl Infect Dis; 2012 Jun 01; 14(3):259-67. PubMed ID: 22093134
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.